The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

NOVEMBER 8, 2023

Marketing Product Manager, Product, NanoTemper Technologies. The luncheon presentation will be done by James Keck, PhD, President’s Innovation Fellow and Senior Director, Innovation and Product Development, Product Development, The Jackson Laboratory.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 9, 2023

Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’. Paul Dyer, PhD, Field Application Scientist, Halo Labs, on: ‘Total particle analysis with aura; pathway to USP validation and product release’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

OCTOBER 27, 2020

“As our core business continues to perform well, we have a solid footing to enter 2021 with several key product launches including the potential INCREASE product label expansion for Tyvaso, the Remunity Pump for Remodulin, and the Implantable System for Remodulin,” said Martine Rothblatt , Ph.D., SILVER SPRING, Md.

Production 40

Production Sales Licensing Licensing 40